Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Variational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis.
Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic Dermatitis
Variational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis.
Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies
Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™Lead Generator to discover first-in-class cancer drugs.
Variational AI and Rakovina announce Collaboration
Rakovina announces potential multi-target engagement with Variational AI focused on DNA Damage Repair (DDR)
